Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Combinatorial protein barcodes enable self-correcting neuron tracing with nanoscale molecular context.
Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025
Expansion in situ genome sequencing links nuclear abnormalities to aberrant chromatin regulation.
Journal: Science (New York, N.Y.)
Published: May 29, 2025
Expansion in situ genome sequencing links nuclear abnormalities to hotspots of aberrant euchromatin repression.
Journal: bioRxiv : the preprint server for biology
Published: October 10, 2024
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 30, 2020
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Journal: Rheumatology (Oxford, England)
Published: March 03, 2020
Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.
Journal: Journal of autoimmunity
Published: November 22, 2019
In situ genome sequencing resolves DNA sequence and structure in intact biological samples.
Journal: Science (New York, N.Y.)
Published: June 19, 2019
Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems.
Journal: Science (New York, N.Y.)
Published: March 08, 2019
Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo.
Journal: Journal of medicinal chemistry
Published: June 29, 2018
Expression of PI3K Signaling Associated with T Cells in Psoriasis Is Inhibited by Seletalisib, a PI3Kδ Inhibitor, and Is Required for Functional Activity.
Journal: The Journal of investigative dermatology
Published: November 08, 2017
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
Journal: Annals of the rheumatic diseases
Published: October 30, 2017
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.
Journal: European journal of clinical pharmacology
Published: October 13, 2016
Last Updated: 09/26/2026